As of 2025-09-16, the Intrinsic Value of Outlook Therapeutics Inc (OTLK) is -4.89 USD. This OTLK valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.05 USD, the upside of Outlook Therapeutics Inc is -565.69%.
Based on its market price of 1.05 USD and our intrinsic valuation, Outlook Therapeutics Inc (OTLK) is overvalued by 565.69%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.89 - -4.89 | -4.89 | -565.69% |
| P/E | (10.56) - (12.54) | (11.56) | -1201.4% |
| DDM - Stable | (7.21) - (28.95) | (18.08) | -1821.9% |
| DDM - Multi | (11.44) - (36.94) | (17.61) | -1777.2% |
| Market Cap (mil) | 46.64 |
| Beta | 0.89 |
| Outstanding shares (mil) | 44.42 |
| Enterprise Value (mil) | 72.18 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.27% |
| Cost of Debt | 5.00% |
| WACC | 8.24% |